Mayo Clinic Study Supports PSA Screening
DALLAS-Of 1,371 men with early-stage prostate cancer (T1c) detected by PSA screening and treated via radical prostatectomy between 1987 and 1996, only three have died of their cancer, Angelo J. Iocca, MD, of the Mayo Clinic, Rochester, Minnesota, said at the American Urological Society annual meeting.
DALLASOf 1,371 men with early-stage prostate cancer (T1c) detected by PSA screening and treated via radical prostatectomy between 1987 and 1996, only three have died of their cancer, Angelo J. Iocca, MD, of the Mayo Clinic, Rochester, Minnesota, said at the American Urological Society annual meeting.
Ten-year local recurrence-free survival, systemic progression-free survival, and systemic/local and/or PSA progression-free survival rates were 96.4%, 99%, and 74.8%, respectively. The findings provide indirect evidence in support of PSA screening as recommended by the AUA and American Cancer Society, he said.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
